Immunophotonics is a private biotechnology company that is developing a proprietary carbohydrate polymer (GC) for use after a common tumor ablation procedure to induce a systemic anti-tumor immune response. Immunophotonics has subsidiaries in Bern, Switzerland and Tianjin, China. We are a multidisciplinary team of highly experienced individuals committed to pioneering the future of cancer immunotherapy.


Immunophotonics is located in the Cortex biotech hub in St. Louis, Missouri near Washington University and Barnes-Jewish Hospital.